Source: HeartCare; Editor: Qi YuanReprint Requirements: If the source of the article is indicated at the beginning of the text, it can be reprinted directly.
Recently,HeartCare (6609.HK)Released the annual report for 2023:In 2023,The company achieved a revenue of 232 million yuan, representing a year-on-year increase of 26.9%.；Achieved a gross profit of 164 million yuan, a year-on-year increase of 31.7%.；Pre-tax loss of 103 million yuan`, year-on-year`Reduced by 48.9%。Stent retrievers and aspiration catheters, dilation balloons and embolic protection systems, as well as coils, etc.Neurointerventional treatment devices contributed 42.3% of sales revenue.(2022: 33.0%),Revenue increased by 62.9% year-over-year.To RMB 98.2 million; neuro-interventional access devices and other products increased by 9.3% year-over-year to RMB 134.1 million.Currently, affected by a combination of economic, policy, and market sentiment factors, the medical device sector continues to experience fluctuations.In an environment of uncertainty, major medical device manufacturers have conveyed a signal in their development process, which isWhile pursuing returns, improve operational and management efficiency, increase growth certainty and competitive advantage.. AndThis pursuit of growth certainty is mainly reflected inCost Control and Efficiency EnhancementAndStrategic FocusTwo Aspects。From an investment logic perspective, this signal offers investors an opportunity to observe innovative medical device companies with investment potential.In 2023,HeartCare not only continues to achieve growth in revenue, but also further narrows its losses, realizing accelerated efficiency.. Let's further discuss from the perspective of investors: how should we view this report card?# Cost Control and Efficiency Enhancement Show Results, Commercialization Accelerates AgainLooking at HeartCare's performance in the first half of the year, the continuously growing commercial revenue and the gradually narrowing losses demonstrate that the company is steadily moving forward on the right track toward commercial success. According to financial reports, in 2023, HeartCare achieved revenue of approximately 232 million yuan, representing a year-on-year increase of 26.9%.HeartCare's performance has achieved steady growth,One important reason lies in cost control.，The company aims to reduce operational management costs and improve profitability by decreasing marketing activities and controlling costs.。In 2023,Corporate Marketing and Management Expenses(Including administrative expenses, sales and distribution expenses) was approximately 154 million yuan, maintaining a continuous downward trend.At the same time, the companyProfitability is also being continuously released.，WithThe expansion of business scale and the effectiveness of cost control and efficiency enhancement measuresIn 2023, the company's gross profit margin increased by 2.6 percentage points to 70.5%, and the proportion of sales and distribution expenses and administrative expenses decreased to 66.2% (2022: 91.8%).On the other hand, the reason lies in the enhancement of efficiency., HeartCareContinuously increase the commercial sales of listed products, expand sales channels, and rapidly increase product market share.。As of now,The company has received NMPA approval for a total of 28 medical device products., widely covering the treatment of acute ischemic stroke and neurovascular stenosis, prevention of ischemic stroke, treatment of hemorrhagic stroke, as well as interventional access, isThe First in ChinaAn interventional medical device company providing one-stop solutions for stroke treatment and prevention。In the first half of the year, driven by policies such as bulk procurement, DRG/DIP reforms, the volume of neurointerventional surgeries in China began to recover, and the pace of import substitution for medical devices continued to accelerate. Relying on its self-established sales channels, HeartCare has expanded its presence across all provinces in China, except for Hong Kong, Macao, and Taiwan.Increase Hospital Penetration and Physician Product Acceptance, continuously strengthening the company's competitiveness and market position in China's neurointervention market.Relying onSteady Expansion of Sales ChannelsHeartCare's management stated at the earnings meeting that the sales of key product pipelines, such as devices for acute ischemic stroke (AIS) thrombectomy, intracranial artery stenosis treatment devices, and innovative access devices, continued to grow in the first half of the year, generating revenue of 96.682 million yuan, a year-on-year increase of 33.1%.In addition, HeartCare has also set its sights on the global market to capture more international market share. CurrentlyThe company has 3 medical device products approved by the FDA for marketing in overseas markets.，A Product Obtains the CE Mark, continuously unlocking more growth points.# Strategic Focus, Multi-dimensional Matrix for Performance Growth PotentialTaking a longer-term perspective, past performance indicates that HeartCare's profitability and business capabilities have been continuously improving. However, the key issue in the future will be how to maintain this growth momentum amidst increasingly fierce industry competition.At this point, HeartCare, relying on its successful experience, abundant resources, and brand influence in the neurointervention market, is steadily promoting the commercialization of more neurointervention medical device products.Rapidly expand into emerging therapeutic areas such as respiratory interventions and active devices, constructing a second growth curve for performance.。In 2023,The company's R&D expenditure was 124 million yuan., with a focus on advancing several cutting-edge research pipelines for the treatment of stroke and pulmonary embolism.Strategic Focus,The positive clinical progress of interventional medical devices indicates that HeartCare's diversified layout is gradually being validated.It is expected that in the near future, as HeartCare's device portfolio gradually enters the commercialization stage, based on a mature and well-established sales network,The product is expected to achieve rapid scaling, making a significant contribution to the company's performance., whose value may also be further enhanced.# From Establishment to IPO in Just Five YearsThe road to domestic substitution has always been arduous.On this road, ahead was Sany Heavy Industry's "Sany Red sweeping the world," ultimately driving Doosan, Hitachi, and other Japanese and Korean competitors out of the market; following behind was Mindray Medical's "encircling the cities from the countryside," tearing a gap in the "GPS medical device iron curtain" formed by GE, Philips, and Siemens.Now, another path of domestically produced alternatives is presented before China's manufacturing industry: neurointerventional medical devices. In this track full of infinite challenges and imagination, a portrait of the winner in the domestically produced alternative pathway is becoming increasingly clear.In just five years, it has transitioned from establishment to IPO, standing as a pioneer in the wave of China-produced alternatives.。This typical representative is preciselyHeartCare, a company focused on minimally invasive interventional technologies for stroke prevention and treatment.A medical device enterprise engaged in the development and industrialization.In 2004,Wang Guohui, a graduate student, joined HeartCare Medical., staying there for a full eight years. During these eight years, HeartCare entered a phase of rapid development and successfully joined the top ranks of China-produced medical device fields. Meanwhile, Wang Guohui also experienced rapid growth during this period. During his tenure, he represented HeartCare in participating in the National Surgical Implant Standardization Technical Committee, leading the revision of dozens of industry standards, which greatly promoted the development of the industry at that time.But Wang Guohui was not satisfied with this; his passion for entrepreneurship continued to burn fiercely.In 2012, Wang Guohui left MicroPort，EstablishedThe first company in China to produce renal artery ablation products for the treatment of resistant hypertension——Antong Medical。By founding HeartCare, Wang Guohui has fully utilized the professional knowledge he accumulated at MicroPort, and his management and operational capabilities have also been honed. In this process,Antong Medical develops rapidly, obtaining the first European marketing authorization for an Asian product within a year., and then strategically cooperated with Terumo, the largest medical device company in Asia, to begin clinical trials in China.The success of Antong Medical did not stop Wang Guohui from moving forward. After this,Wang Guohui also founded another company focused on the coronary field,Bioheart Biotech, this company dedicated to absorbable coronary drug-eluting stents, has now developed into the third-largest player in China's biodegradable stent market, with its products entering the final clinical stage.As Antong Medical and Baixinan Bio gradually got on track, Wang Guohui felt that the company affairs no longer required so much of his energy. As an entrepreneur, his restless heart was once again stirred. In early 2016, an occasional neurointervention forum made Wang Guohui realize that the domestic market for neurointerventional products was almost monopolized by imports, with high prices and insufficient supply, leaving many diseases without dedicated interventional products."The market for high-value consumables in the cardiac field has already seen the emergence of multiple listed companies, while the share of domestically produced neurointerventional products remains relatively low. I believe that what can be achieved in the coronary intervention field with domestic production should also be possible in the neurointervention field. We, as professionals in the vascular field, should do something to support the domestic production of neurointerventional products." With this original intention,In 2016, Wang Guohui founded HeartCare, focusing on products for the treatment of stroke through combined heart and brain solutions.。This decision quickly garnered significant attention from the capital market. Less than a year after its establishment, HeartCare secured an angel round of financing worth tens of millions of yuan. Following this, it continued to be highly favored by the capital market, completing five rounds of financing between 2018 and 2020. Notably,Before its listing in 2020, HeartCare completed three rounds of financing within a year, with a total financing amount reaching up to 1 billion yuan., which has, to a certain extent, accelerated the listing process of HeartCare.# About HeartCare
HeartCare was founded in 2020 and isPioneer of Neurointerventional Medical Devices in China, with the goal of redefining the treatment and prevention standards for stroke. Relying on the company’s comprehensive capabilities in R&D, production, and commercialization, HeartCare is committed to reducing the mortality rate of stroke and improving prognosis in China and globally by commercializing innovative products under development.
As of the announcement date,CompanyYes28 ModelsMedical Device Product Receives NMPA Approval、Three Medical Devices Gain FDA Approval and One Product Receives CE Mark，covering various neurointerventional procedures for the treatment and prevention of stroke.
NMPA Pipeline:
FDA and European Conformity (CE) Pipeline:
In the next 24 months, our company expectsAt Least Five Major Neurointerventional Treatment Devices to Hit the Market, including drug-coated balloons for stenosis treatment (NMPA innovative device qualification), self-expanding drug-eluting stents, and carotid artery stents, as well as aneurysm embolization assist stents (NMPA innovative device qualification) and flow diverter devices for the treatment of hemorrhagic stroke.
At the same time, our company addresses the emergency surgery needs for different subtypes of cerebral infarction,Enhance the competitiveness of key thrombectomy products (aspiration catheters and thrombectomy stents) and one-stop medical device solutions., to meet the growing demand for stroke treatment in China amidst an aging population.
In terms of overseas markets, the thrombectomy stent, occlusion balloon catheter, distal access catheter, and microcatheter of our company have obtained CE or FDA certification, and have completed registration and initiated commercialization in countries or regions such as Thailand. As of now,The company is also conducting product registration in 10 other countries or regions., expand sales channels, and lay the foundation for achieving long-term goals in overseas sales.
# Future and Prospects
Enhance the company's brand awareness as a comprehensive neurointerventional device solutions provider in the market, expand the sales of commercialized neurointerventional products, and rapidly advance the commercialization of products under development;
Further improve manufacturing capabilities to ensure a highly reliable product supply;
Drive the development of innovative medical devices in emerging therapeutic areas with high growth potential to form a second business unit with a competitive commercial product portfolio outside of the neurointervention business.
